Skip to content

Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia

Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01141673
Enrollment
100
Registered
2010-06-10
Start date
2010-06-30
Completion date
2011-06-30
Last updated
2011-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

FLT3-ITD, acute myeloid leukemia, FLT3, D835

Brief summary

FLT3 overexpression in acute myeloid leukemia (AML) is often caused by mutations in this gene. These mutations cause constitutive phosphorylation of FLT3 proteins leading to increased proliferation and survival, decreased apoptosis and resistance to chemotherapeutic agents in AML cells. There are two major types of FLT3 mutations- internal tandem duplication (ITD) and point mutation at 835th amino residue. AMLs with FLT3 mutations have worse prognosis and are often resistant to conventional chemotherapy. Several small molecule compounds targeting FLT3 have been in the market or in clinical trials. Therefore, identification of these mutations at the time of diagnosis will provide a better prognostic prediction, might guide the treatment selection and follow-up strategies. In this study, the investigators will develop a sensitive molecular assay to detect FLT3 mutations for future clinical application. The investigators will collect 100 AML samples with at least 20 samples with known FLT3 mutations. The investigators will compare this assay with commonly used methods and standardize the procedure to meet the requirement of clinical pathology laboratory with reasonable cost.

Interventions

None listed

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with confirmed diagnosis of acute myeloid leukemia

Exclusion criteria

* non

Countries

Taiwan

Contacts

Primary ContactHsin-Gjin Eugene Liu
liuxx086@gmail.com886-2-29307930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026